7 days ago
UBS Reaffirms Their Buy Rating on Novo Nordisk (0QIU)
UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) on May 31 and set a price target of DKK700.00.
Confident Investing Starts Here:
Walton covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Bayer, and Sanofi. According to TipRanks, Walton has an average return of -0.5% and a 52.08% success rate on recommended stocks.
In addition to UBS, Novo Nordisk also received a Buy from Deutsche Bank 's Emmanuel Papadakis in a report issued on May 27. However, on May 16, Berenberg Bank maintained a Hold rating on Novo Nordisk (LSE: 0QIU).
0QIU market cap is currently DKK2013.8B and has a P/E ratio of 19.73.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0QIU in relation to earlier this year.
